1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsMusculoskeletal Tissue Engineering and Regenerative Medicine Program is sponsored by National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), NIH. This opportunity supports mission-aligned projects and measurable outcomes.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Musculoskeletal Tissue Engineering and Regenerative Medicine Program | NIAMS This program supports basic and translational research in the repair, regeneration, and restoration of function of injured and/or diseased musculoskeletal tissues using stem cell biology and engineering-based approaches. These tissues include bone, cartilage, tendon, ligament, menisci, muscle and intervertebral discs.
Multi- and inter- disciplinary research teams with expertise in biological and physical sciences and cross-training for emerging scientists are encouraged. Areas of supported research include the following: Pathways of human organogenesis - how cells self-assemble into complex tissues in vitro and in vivo .
Cellular processes of mammalian stem and progenitor cells - controlling survival, differentiation, proliferation, migration, senescence, and responses to stimuli. Role of inflammation and responses to immune signals. Smart scaffolds for structural, mechanical, and functional support.
Micro environment to promote repair and regeneration. Developing effective strategies to Recruit and direct endogenous progenitor or stem cells. Integrate engineered tissues with the host while reducing adverse effects (e.g., immunogenicity, toxicity).
Improve molecular, cellular, or gene-based therapies. Cell optimization and scale-up. Tissue preservation and storage.
Real-time, non-invasive modalities to track cells, and/or monitor tissue-function repair and integration process in vivo . Establish models, such as: 3-D human tissue models for drug screening or studying pathophysiological processes. Preclinical models to promote direct clinical translation.
Exploring cross-talk between regeneration and rehabilitation to restore functions. Building: Democracy 1, Suite 800
According to the current listing, eligibility includes: Universities, non-profit research institutions, medical schools, small businesses (depending on FOA). Confirm the full requirements in the official notice before applying.
Musculoskeletal Tissue Engineering and Regenerative Medicine Program is funded by National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), NIH. Verify program details on the funder's official page before applying.
Yes — this listing is flagged as national in scope, so applicants across the U.S. may apply, subject to the sponsor's other eligibility criteria.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
PA-27-037 consolidates the Predoctoral to Postdoctoral Transition Award into a single parent announcement across 20 NIH components, with the next deadline December 8, 2026. The eligibility gate is not the science — it is a mandatory change of institution and mentor between the F99 and K00 phases.
Read articleA draft executive order would have put OMB Director Russell Vought on a commission with final say over NIH awards after peer review. Sen. Collins killed it by pointing at a provision Congress already passed. Here is what the episode teaches applicants about the December 11 cliff.
Read articlePA-27-034, PA-27-035 and PA-27-036 replace the institute-specific R25 announcements that research education programs have been built around for a decade. NCI, NIDA and NIGMS have already expired theirs early. Here is what the consolidation actually changes: an 8% indirect cost ceiling, a US-citizens-and-permanent-residents participant rule, a cooperative agreement variant that only exists on one of the three, and no clinical-trial-allowed companion anywhere.
Read article